Abstract

The innovative drug development of antiretroviral therapy (ART) has significantly improved the life expectancy of patients with human immunodeficiency virus (HIV) significant increase in the number of elderly individuals with HIV has been observed [1-15]. The complexity of ageing, HIV infection, and ART exposure may alter the risk of comorbid conditions such as cardiovascular disease, metabolic syndromes, or mental disorders in these HIVinfected individuals.As a result, medications were prescribed to address unfavourable comorbidities. Concomitant medications, on the other hand, may contribute to pill burden and drug-drug interactions (DDIs) in the HIV-infected population.

DDIs should be monitored in HIV patients because they can alter the effectiveness and safety of ART or other medications, resulting in negative clinical outcomes. Increased drug exposure of HIV/non-HIV medications may result in unwanted side effects. 5 Subtherapeutic drug concentrations associated with a DDI, on the other hand, may result in the rebound of plasma HIV RNA and ART drug resistance.